AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35794614 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia techniques
Number of subjects: 221
Study 35794614 — intervention group
Group type: EXPERIMENTAL
Intervention: Double injection erector spinae plane block
Number of subjects: 221
Study 35794616 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAR-B38M
Number of subjects: 74
Study 35794623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg bid in combination with pembrolizumab 200 mg Q3W
Number of subjects: 13
Study 35794623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid in combination with pembrolizumab 200 mg Q3W
Number of subjects: 13
Study 35794623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid
Number of subjects: 13
Study 35794623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg bid
Number of subjects: 13
Study 35794623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib and pembrolizumab therapy
Number of subjects: 13
Study 35794669 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time digital alerts from wearable sensors
Number of subjects: 50
Study 35794669 — intervention group
Group type: COMPARATOR
Intervention: Standard intermittent ward monitoring of vital signs by nurses
Number of subjects: 50
Study 35794781 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) intervention
Number of subjects: 60
Study 35794793 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of NTHi species
Number of subjects: 0
Study 35794793 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain apparition of NTHi
Number of subjects: 0
Study 35794884 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic transabdominal pre-peritoneal hernia repairs (rTAPP)
Number of subjects: 0
Study 35794884 — intervention group
Group type: COMPARATOR
Intervention: Totally extra-peritoneal hernia repairs (TEP)
Number of subjects: 0
Study 35795028 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical indexes including white blood cell (WBC), uric acid (UA), direct bilirubin (DBIL), lactic dehydrogenase (LDH), fasting blood glucose (FBG), and low-density lipoprotein (LDL)
Number of subjects: 4613
Study 35795028 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model using multivariable logistic regression
Number of subjects: 4613
Study 35795028 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional biochemical index
Number of subjects: 4613
Study 35795051 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised circuit aerobic and resistance exercise (CARE) program
Number of subjects: 276
Study 35795051 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional aerobic and resistance exercise (TARE) program
Number of subjects: 276
Study 35795051 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 276
Study 35795051 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE, TARE, and AC groups
Number of subjects: 276
Study 35795231 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of the LARS score (tested twice)
Number of subjects: 205
Study 35795231 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 questionnaire
Number of subjects: 205
Study 35795367 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV)
Number of subjects: 312
Study 35795367 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment of CSA)
Number of subjects: 312
Study 35795492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 300 mg twice daily
Number of subjects: 0
Study 35795492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 600 mg twice daily
Number of subjects: 0
Study 35795492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35795629 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Virtual Reality training for chemotherapy administration
Number of subjects: 83
Study 35795629 — intervention group
Group type: COMPARATOR
Intervention: Document reading (Control)
Number of subjects: 83
Study 35795849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraovarian injection of platelet-rich plasma (PRP) (1.5 ml) with an average of 12 injections per ovary.
Number of subjects: 80
Study 35796199 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 0
Study 35796199 — intervention group
Group type: COMPARATOR
Intervention: ravulizumab
Number of subjects: 0
Study 35796536 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccination
Number of subjects: 745
Study 35796561 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk education, coping skills training, physical activity, and stress management
Number of subjects: 41
Study 35796561 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 41
Study 35796785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride (10-min dosing)
Number of subjects: 37
Study 35796785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m
Number of subjects: 37
Study 35797012 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with pertuzumab (840 mg first cycle, 420 mg subsequent cycles), atezolizumab (1200 mg), docetaxel (75 mg/m2), and trastuzumab (600 mg subcutaneous) every 3 weeks for 6 cycles.
Number of subjects: 67
Study 35797012 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for patients with pCR: 12 cycles of atezolizumab, trastuzumab, and pertuzumab every 3 weeks after surgery.
Number of subjects: 67
Study 35797012 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for patients without pCR: 14 cycles of atezolizumab (1200 mg) plus trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
Number of subjects: 67
Study 35797012 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (overall treatment)
Number of subjects: 67
Study 35797174 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture cues
Number of subjects: 0
Study 35797174 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly salient targets
Number of subjects: 0
Study 35797174 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent targets
Number of subjects: 0
Study 35797174 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salience target
Number of subjects: 0
Study 35797174 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down guidance
Number of subjects: 0
Study 35797174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up guidance
Number of subjects: 0
Study 35797174 — intervention group
Group type: COMPARATOR
Intervention: AD patients
Number of subjects: 0
Study 35797356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 141
Study 35797356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus resistance exercise
Number of subjects: 141
Study 35797356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus aerobic exercise
Number of subjects: 141
Study 35797356 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 141
Study 35797460 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 35797460 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 0
Study 35797460 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical options
Number of subjects: 0
Study 35797460 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests for rare genetic causes of obesity
Number of subjects: 0
Study 35797864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment
Number of subjects: 11764
Study 35798000 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous mRNA vaccine boosting
Number of subjects: 0
Study 35798000 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous mRNA and Ad26.COV2.S vaccine boosting
Number of subjects: 0
Study 35798000 — intervention group
Group type: COMPARATOR
Intervention: Homologous Ad26.COV2.S boosting
Number of subjects: 0
Study 35798027 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged surgical mask use
Number of subjects: 0
Study 35798027 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0
Study 35798027 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35798241 — intervention group
Group type: EXPERIMENTAL
Intervention: SH-1028 (200 mg/d orally until disease progression or intolerable toxicity)
Number of subjects: 286
Study 35798401 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR derived from coronary computed tomography angiography revascularization planner (FFR)
Number of subjects: 120
Study 35798405 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 35798468 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1-based treatment after cardiotoxicity from capecitabine or 5-FU
Number of subjects: 200
Study 35798468 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1-based treatment
Number of subjects: 200
Study 35798532 — intervention group
Group type: EXPERIMENTAL
Intervention: Long diagnostic delay (>1 year)
Number of subjects: 264
Study 35798532 — intervention group
Group type: COMPARATOR
Intervention: Short diagnostic delay (<1 year)
Number of subjects: 264
Study 35798714 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 F-CAR-T
Number of subjects: 25
Study 35799070 — intervention group
Group type: EXPERIMENTAL
Intervention: BiliSpec
Number of subjects: 375
Study 35799070 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous bilirubinometer
Number of subjects: 375
Study 35799070 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (spectrophotometry)
Number of subjects: 375
Study 35799116 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum thyroid-stimulation hormone (TSH) levels
Number of subjects: 1862
Study 35799116 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TSH levels after adjusting for age and other risk factors
Number of subjects: 1862
Study 35799290 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA prescription (≥3 canisters)
Number of subjects: 301
Study 35799290 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA prescription (≥10 canisters)
Number of subjects: 301
Study 35799290 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA purchased OTC
Number of subjects: 301
Study 35799290 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA prescription and OTC purchase
Number of subjects: 301
Study 35799290 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control status
Number of subjects: 301
Study 35799290 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe exacerbations
Number of subjects: 301
Study 35799302 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC-OUT score < 6 points
Number of subjects: 1469
Study 35799302 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC-OUT score
Number of subjects: 1469
Study 35799302 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian insertion site
Number of subjects: 1469
Study 35799302 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of 1,469 CVCs
Number of subjects: 1469
Study 35799394 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib (160 mg bid, orally, 28-day cycles)
Number of subjects: 48
Study 35799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of total fat
Number of subjects: 62
Study 35799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of saturated fatty acids
Number of subjects: 62
Study 35799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of carbohydrates
Number of subjects: 62
Study 35799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of fiber
Number of subjects: 62
Study 35799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient intake (vitamin A, D, folate, calcium)
Number of subjects: 62
Study 35799579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D, calcium, and riboflavin intake
Number of subjects: 62
Study 35799791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 67
Study 35799975 — intervention group
Group type: EXPERIMENTAL
Intervention: IYPB intervention (76 families)
Number of subjects: 112
Study 35799975 — intervention group
Group type: COMPARATOR
Intervention: Usual care (36 families)
Number of subjects: 112
Study 35800013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided internal branch of the upper laryngeal nerve (USG-guided iSLN) block combined with general anesthesia
Number of subjects: 80
Study 35800013 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anesthesia only)
Number of subjects: 80
Study 35800017 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Social Cognitive and Behavioral Skill Therapy (ISST)
Number of subjects: 180
Study 35800017 — intervention group
Group type: COMPARATOR
Intervention: Neurocognitive Remediation Therapy (NCRT)
Number of subjects: 180
Study 35800360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary reteplase (9 mg or 18 mg)
Number of subjects: 306
Study 35800668 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable electrocardiogram (ECG)
Number of subjects: 55
Study 35800670 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of tramadol 37.5 mg/acetaminophen 325 mg ER FDC (DW-0920)
Number of subjects: 0
Study 35800670 — intervention group
Group type: COMPARATOR
Intervention: One tablet of tramadol 75 mg/acetaminophen 650 mg
Number of subjects: 0
Study 35801187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg every 2 weeks for 12 weeks)
Number of subjects: 14
Study 35801187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 14
Study 35801558 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion-based, standardised, two-phase therapy protocol
Number of subjects: 8
Study 35801588 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-nucleocapsid IgG level in the first week after positive RT-PCR test
Number of subjects: 617
Study 35801588 — intervention group
Group type: EXPERIMENTAL
Intervention: History of lung disease
Number of subjects: 617
Study 35801588 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 disease severity, ethnicity, age, sex, and remdesivir use
Number of subjects: 617
Study 35801588 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first resolution of all symptoms
Number of subjects: 617
Study 35801588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained symptom resolution
Number of subjects: 617
Study 35801588 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 syndrome
Number of subjects: 617
Study 35801762 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble contrast agent (iohexol) swallowing study (WSS)
Number of subjects: 762
Study 35801762 — intervention group
Group type: COMPARATOR
Intervention: Modified barium swallowing study (MBSS)
Number of subjects: 762
Study 35801788 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed spinal anesthesia group
Number of subjects: 110
Study 35801788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 35801795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen at a flow rate of 2 L kg-1 min-1
Number of subjects: 27
Study 35801795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 27
Study 35801915 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 964
Study 35801915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 964
Study 35802001 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based therapy (mixed-method cognitive behavioral therapy)
Number of subjects: 50
Study 35802001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 50
Study 35802063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (400 mg/100 mg) daily for 12 weeks
Number of subjects: 37
Study 35802252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX)
Number of subjects: 245
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Interventions to improve communication (e.g. question prompt list, with or without patient and physician training)
Number of subjects: 8
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Interventions to improve EoL communication
Number of subjects: 8
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Family conference intervention
Number of subjects: 8
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Structured serious illness conversation guide
Number of subjects: 8
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Communication interventions (e.g. structured EoL conversations)
Number of subjects: 8
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Communication interventions (e.g. question prompt list alone or with nurse-led communication skills training)
Number of subjects: 8
Study 35802350 — intervention group
Group type: COMPARATOR
Intervention: Interventions to improve communication
Number of subjects: 8
Study 35802393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of autologous adult bone marrow mononuclear cells (BMMNCs)
Number of subjects: 176
Study 35802402 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship Bench (FB) program, a problem-solving therapy (PST)-based program adapted for use among people living with HIV on MMT.
Number of subjects: 0
Study 35802405 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine U300 (IGlar-300)
Number of subjects: 25
Study 35802405 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec U100 (IDeg-100)
Number of subjects: 25
Study 35802628 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (15 minutes)
Number of subjects: 62
Study 35802786 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS negative at screening
Number of subjects: 70
Study 35802786 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS positive at screening
Number of subjects: 70
Study 35802786 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS colonization
Number of subjects: 70
Study 35802786 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS-specific antibodies
Number of subjects: 70
Study 35802786 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of antibody levels
Number of subjects: 70
Study 35803260 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4
Number of subjects: 0
Study 35803286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (1 mg on cycle 1 day 1, 2 mg on cycle 1 day 8, 60 mg on cycle 1 day 15 and cycle 2 day 1, 30 mg on day 1 of cycle 3 and onwards)
Number of subjects: 90
Study 35803286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 90
Study 35803294 — intervention group
Group type: EXPERIMENTAL
Intervention: CEND-1 plus nab-paclitaxel and gemcitabine
Number of subjects: 31
Study 35803294 — intervention group
Group type: EXPERIMENTAL
Intervention: CEND-1 monotherapy
Number of subjects: 31
Study 35803731 — intervention group
Group type: EXPERIMENTAL
Intervention: Woven EndoBridge (WEB) device treatment
Number of subjects: 100
Study 35803835 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib treatment in gBRCAm cohort
Number of subjects: 272
Study 35803835 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib treatment in sBRCAm cohort
Number of subjects: 272
Study 35803835 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib treatment in HRD-positive cohort
Number of subjects: 272
Study 35803835 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib treatment in HRD-negative cohort
Number of subjects: 272
Study 35804188 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 therapy
Number of subjects: 122
Study 35804188 — intervention group
Group type: COMPARATOR
Intervention: Patients who discontinued radium-223 therapy
Number of subjects: 122
Study 35804294 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg intravenous every 12 weeks for up to 8 doses
Number of subjects: 128
Study 35804359 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 0
Study 35804359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis tools for patient navigation
Number of subjects: 0
Study 35804359 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder engagement methods
Number of subjects: 0
Study 35804385 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Culuan Decoction 13 g three times a day for 14 days and clomiphene citrate placebo tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period.
Number of subjects: 0
Study 35804385 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period (control group).
Number of subjects: 0
Study 35804404 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sirolimus solution (1 mg/mL) applied once daily for 24 weeks
Number of subjects: 0
Study 35804404 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no treatment)
Number of subjects: 0
Study 35804409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal transcriptomics (Transcriptomic Subgroup B or D)
Number of subjects: 63
Study 35804409 — intervention group
Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 63
Study 35804409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal transcriptomics
Number of subjects: 63
Study 35804409 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarkers
Number of subjects: 63
Study 35804417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mammography unit in addition to current OBCS
Number of subjects: 0
Study 35804417 — intervention group
Group type: COMPARATOR
Intervention: Current OBCS without mobile unit
Number of subjects: 0
Study 35804453 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended prone positioning (median duration 39 hours)
Number of subjects: 81
Study 35804454 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment: rifampicin plus clarithromycin for 8 weeks
Number of subjects: 70
Study 35804454 — intervention group
Group type: COMPARATOR
Intervention: Investigational treatment: rifampicin plus clarithromycin plus amoxicillin/clavulanate for 4 weeks
Number of subjects: 70